A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis
about
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromesTreatment of nongout joint deposition diseases: an updatePathophysiological consequences and benefits of HFE mutations: 20 years of research.Non-HFE hemochromatosisDiagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.Deferasirox: appraisal of safety and efficacy in long-term therapy.Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice.Deferasirox: pharmacokinetics and clinical experience.Molecular diagnostic and pathogenesis of hereditary hemochromatosis.Diagnosis and treatment of hereditary hemochromatosis: an update.Deferasirox nephrotoxicity-the knowns and unknowns.How we manage patients with hereditary haemochromatosis.Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.Diabetes mellitus caused by secondary hemochromatosis after multiple blood transfusions in 2 patients with severe aplastic anemia.Juvenile hemochromatosis: HAMP mutation and severe iron overload treated with phlebotomies and deferasirox.
P2860
Q26771519-E6789BBB-245A-4224-8206-AA0F330D1EBAQ26852957-25AE654B-BA46-4DD6-B4AC-1731EF7461CCQ33815961-F1F153A8-E0FD-4872-80F0-27607B53E9D5Q34304892-48F35416-75EE-4988-B461-731F95615173Q35144263-36F86034-3032-4D96-8845-C7C77F028745Q35683841-7F7C19FE-BC09-4E5D-864E-3CDFD60470E3Q37095523-8F1955D6-4F0A-477D-A0B6-D4CC91E3CE1CQ37928941-392B6224-AF9A-4979-BBF0-5F3405022B5AQ37969225-4B7EB953-76C4-44D9-9CD3-FD48A738735DQ37992618-ACF8D800-9987-481F-B90D-533D0BC2253EQ38132275-BE0BA35D-AE32-4F18-B798-343EDF331AB8Q38232442-CB9D3A52-D2E2-42D4-BD02-BCC135534FDBQ38813097-8B7BCF3E-D3FF-4C95-A2C8-5F5BAFF6CD49Q41432463-1C6E02EB-5FCF-474E-9F90-DCD813299C76Q41837287-4D313A50-B931-4E8A-8ABC-76B8D923975CQ47123552-E084F2EB-DF03-44B8-9860-43F906DF5ECF
P2860
A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase 1/2, dose-escalation t ...... ted hereditary hemochromatosis
@ast
A phase 1/2, dose-escalation t ...... ted hereditary hemochromatosis
@en
A phase 1/2, dose-escalation t ...... ted hereditary hemochromatosis
@nl
type
label
A phase 1/2, dose-escalation t ...... ted hereditary hemochromatosis
@ast
A phase 1/2, dose-escalation t ...... ted hereditary hemochromatosis
@en
A phase 1/2, dose-escalation t ...... ted hereditary hemochromatosis
@nl
prefLabel
A phase 1/2, dose-escalation t ...... ted hereditary hemochromatosis
@ast
A phase 1/2, dose-escalation t ...... ted hereditary hemochromatosis
@en
A phase 1/2, dose-escalation t ...... ted hereditary hemochromatosis
@nl
P2093
P2860
P50
P356
P1433
P1476
A phase 1/2, dose-escalation t ...... ted hereditary hemochromatosis
@en
P2093
Claus Niederau
Gordon D McLaren
Herbert L Bonkovsky
John Gross
Lawrie W Powell
Louis Griffel
Mark W Russo
Mark Wurster
Nicola Lynch
Paul C Adams
P2860
P304
P356
10.1002/HEP.23879
P407
P577
2010-11-01T00:00:00Z